Berberine hydrochloride tablets,
does it really help with Reduced weekly diarrhea frequency in diarrhea-predominant irritable bowel syndrome?
research showsGrade C with 50 points. At week 8, diarrhea frequency was 1.39 with berberine versus 3.55 with the vitamin-C control (P=.032), but at week 12 it was 3.58 versus 3.81 (P=.805). Recruitment, randomization, and completion denominators are inconsistent, and no 95% CI was reported.
ads claimDo not expand this to cure, relapse prevention, microbiome normalization, or the same effect on pain and quality of life.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. Diarrhea, constipation, and abdominal symptoms from the intervention can overlap with the condition itself. Avoid or clinically review use in pregnancy, lactation, infancy, and with CYP-related medicines.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine-hydrochloride.oral.ibs-diarrhea-frequency.reduce.vitamin-cSupplements and nutraceuticals > Berberine hydrochloride > Oral > IBS-D diarrhea frequency > Reduction claim > Vitamin C tablet control
Bound to diarrhea frequency after 400 mg/day for eight weeks; pain, urgency, quality of life, and the four-week off-treatment result are separate. The paper's placebo was vitamin C. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine hydrochloride |
| Source or part used | Purified berberine hydrochloride; source plant unverified |
| Formulation or processing | 200-mg berberine hydrochloride tablets |
| Route | Oral |
| Dose | 200 mg twice daily (400 mg/day) |
| Duration | Eight weeks of treatment plus four weeks off treatment |
| Population | Adults with Rome III diarrhea-predominant IBS |
| Effect or condition | Lower weekly diarrhea frequency |
| Primary endpoint | Diary-recorded weekly diarrhea episodes |
| Comparator | Vitamin C tablets 400 mg/day |
| Duplicate-detection key | Berberine hydrochloride|200-mg berberine hydrochloride tablets|Oral|Adults with Rome III diarrhea-predominant IBS|Lower weekly diarrhea frequency|Eight weeks of treatment plus four weeks off treatment |
What the research actually shows
Tables and methods in the full PDF were checked against the abstract to verify the vitamin-C control and time-specific values.
Why this is classified as C (50)
Axes are P/R1/I2/EX/B2/CX with coprimary_split. I2 is one strength, but small, short, completer-based evidence and endpoint splitting yield C/50.
Counterpoint. The end-of-treatment signal may matter to patients, but the post-discontinuation null result and denominator/control issues reduce certainty.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 62 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Berberine Hydrochloride for IBS-D Diarrhea Frequency—Lower at Eight Weeks, With No Difference Four Weeks After Stopping — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/berberine-hydrochloride-ibs-d-diarrhea-frequency/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.